Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

Nature Clinical Practice Oncology volume 5, pages 506–507 (2008)Cite this article

Abstract

This Practice point commentary discusses the findings of a randomized, multicenter, report published by Berthold et al, in which the results of the pivotal TAX 327 study are updated. The original TAX 327 study, published in 2004, randomly allocated men with castration-resistant prostate cancer to one of three chemotherapy regimens: docetaxel 75 mg/m2 administered every 3 weeks, docetaxel 30 mg/m2 administered weekly for 5 of every 6 weeks, or mitoxantrone 12 mg/m2 every 3 weeks. All patients received prednisone 5 mg twice daily. The original trial showed a significant survival benefit for those patients receiving docetaxel every 3 weeks compared with those receiving mitoxantrone. The updated analysis demonstrates that docetaxel remains the standard first-line chemotherapy for patients with castration-resistant prostate cancer. This commentary highlights the key results that were updated from the original TAX 327 study and also discusses several unresolved issues, including the optimum timing of chemotherapy initiation and its duration.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. American Cancer Society. Cancer facts & figures 2007. [http://www.cancer.org/docroot/STT/stt_0_2007.asp?sitearea=STT&level=1] (accessed 23 April 2008)

  2. Food and Drug Administration (online 19 May 2004) FDA approves new indication for taxotere—prostate cancer. [http://www.fda.gov/bbs/topics/news/2004/NEW01068.html] (accessed 3 June 2008)

  3. Food and Drug Administration (online 13 November 1996) FDA approves new drug for treating prostate cancer. [http://www.fda.gov/bbs/topics/ANSWERS/ANS00771.html] (accessed 3 June 2008)

  4. Osoba D et al. (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17: 1654–1663

    Article  CAS  Google Scholar 

  5. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  6. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  Google Scholar 

  7. Berthold DR et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242–245

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. B Schurko is a Clinical Research Coordinator for Genitourinary Oncology at Dana–Farber Cancer Institute, and WK Oh is an Associate Professor of Medicine at Harvard Medical School, and Clinical Director at the Lank Center for Genitourinary Oncology, Dana–Farber Cancer Institute, Boston, MA, USA.,

    Brian Schurko & William K Oh

Authors
  1. Brian Schurko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William K Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William K Oh.

Ethics declarations

Competing interests

B Schurko declared no competing interests. WK Oh receives grant/research support from Genentech and is a Consultant on the Speakers Bureau and receives grant/research support from Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schurko, B., Oh, W. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Rev Clin Oncol 5, 506–507 (2008). https://doi.org/10.1038/ncponc1201

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1201

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing